Lipella Pharmaceuticals Inc.
LIPO
$2.52
-$0.005-0.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -5.02M | -4.26M | -4.14M | -4.74M | -4.62M |
| Total Depreciation and Amortization | 2.90K | 2.90K | 3.20K | 1.80K | 1.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 949.40K | 868.70K | 909.30K | 1.67M | 1.48M |
| Change in Net Operating Assets | 113.30K | -296.10K | -494.20K | -390.80K | -9.00K |
| Cash from Operations | -3.95M | -3.69M | -3.72M | -3.46M | -3.15M |
| Capital Expenditure | -- | 0.00 | -14.40K | -14.40K | -14.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 0.00 | -14.40K | -14.40K | -14.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | 0.00 | -250.00K | -275.00K |
| Issuance of Common Stock | 2.84M | 2.63M | 1.81M | 1.81M | 1.61M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.84M | 2.63M | 1.81M | 1.56M | 1.34M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | 0.00 | -- | -- |
| Net Change in Cash | -1.11M | -1.06M | -1.93M | -1.91M | -1.83M |